CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Republic of China (Taiwan)

Date: 2015-08

“CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Republic of China (Taiwan)


GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Republic of China (Taiwan)”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the Republic of China (Taiwan). It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

Taiwan’s population increased slightly between 2008 and 2013 from 23.0 to 23.4 million, mainly due to a rising life expectancy. However, the birth rate decreased at a negative Compound Annual Growth Rate (CAGR) of 0.2%. The pharmaceutical market was estimated at $5.4 billion in 2013 and is projected to reach $8.4 billion by 2020 at a CAGR of 6.4%. The medical device market was worth $2.2 billion in 2013 and is projected to reach $3.1 billion by 2020 at a CAGR of 5.3%, primarily attributed to an increasingly elderly population, and universal healthcare coverage. Government initiatives, such as a reduction in income tax for new pharmaceutical companies that establish themselves in Taiwan, are intended to encourage foreign companies to invest and will further boost the market.


The report provides information on the healthcare, regulatory, and reimbursement landscape in Taiwan, and includes –
– An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
– Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Sanofi, GlaxoSmithKline, Yung Shin Pharmaceutical, and China Chemical & Pharmaceutical; and of major players in the medical device market: Baxter International, Fresenius Medical Care, Siemens Healthcare, GE Healthcare, and China Chemical & Pharmaceutical
– Insightful review of the reimbursement and regulatory landscape, with analysis covering details of the healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices
– Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure, and healthcare expenditure
– An overview of the opportunities for and challenges to growth in the Taiwanese healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to –
– Develop business strategies by understanding the trends shaping and driving Taiwan’s healthcare market
– Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to affect Taiwan’s healthcare market in the future
– Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of competitors
– Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment, and strategic partnership
– Identify, understand, and capitalize on the opportunities and challenges in Taiwan’s healthcare market”

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample